BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Alamar Biosciences Expands APAC Presence with Five New Distribution Partnerships

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce the signing of five new dis...

March 20, 2025 | News

Akeso’s Penpulimab Secures NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National ...

March 18, 2025 | News

Advancing Cell & Gene Therapy in APJ: How Thermo Fisher Enables Breakthrough Innovation

What are the most significant recent breakthroughs in cell and gene therapy and how is Thermo Fisher Scientific involved in these advancements? In 2024, t...

March 14, 2025 | Interaction

Japan Grants Orphan Drug Designation to Lundbeck’s Amlenetug for Multiple System Atrophy

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetu...

March 11, 2025 | News

NEC Partners with Nagasaki University and CEPI to Advance AI-Driven mRNA Vaccine for SFTS and Future Epidemic Threats

NEC Partners with Nagasaki University and CEPI to Develop AI-Driven mRNA Vaccine for SFTS and Future Epidemic Threats NEC Corporation (NEC; TSE: 6701) has...

March 10, 2025 | News

Merck Life Science Expands in Japan with New Tokyo Office

Merck Life Science, a global leader in the life sciences sector, has strengthened its commitment to the Japanese market with the inauguration of a new offi...

March 06, 2025 | News

Daiichi Sankyo and AstraZeneca’s ENHERTU Recommended for EU Approval for HER2 Low and HER2 Ultralow Metastatic Breast Cancer

Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in th...

March 03, 2025 | News

WuXi Biologics Passes Japan’s PMDA GMP Inspection for Wuxi Drug Substance Facilities

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has...

February 28, 2025 | News

Japan’s AMR Response 2013–2025: Key Lessons and Global Implications

The World Health Organization (WHO) Regional Office for the Western Pacific (WPRO) has released Japan’s AMR Response 2013–2025, providing a com...

February 26, 2025 | News

TriNetX and Fujitsu Launch Joint Venture to Transform Clinical Research in Japan

TriNetX, a global leader in real-world data (RWD) and real-world evidence (RWE) solutions, has partnered with Fujitsu, a global ICT company and one of...

February 13, 2025 | News

PHC Corporation Partners with CCRM to Advance T-Cell Expansion for Cell and Gene Therapies

PHC Corporation has signed a Master Collaboration Agreement with CCRM, a global leader in regenerative medicine and biomanufacturing, to jointly develop pr...

February 12, 2025 | News

Pfizer and Astellas Announce Sustained Survival Benefit in Advanced Urothelial Cancer with PADCEV® and KEYTRUDA® Combination

Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination a...

February 11, 2025 | News

Daiichi Sankyo & AstraZeneca’s Datopotamab Deruxtecan Recommended for EU Approval After Cutting Disease Progression Risk by 37%

Recommendation based on TROPION-Breast01 results showing Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced risk of disease prog...

February 03, 2025 | News

GHIT Fund Invests JPY 2 Billion (USD 12.7M) in Diagnostics and Drug Development for NTDs and Malaria

The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 2 billion (USD 12.7 million) in eight projects ...

January 30, 2025 | News

Stay Connected